Pentadecanoic acid, known as C15, is a saturated odd-chain fatty acid found naturally in full-fat dairy products and ruminant fats. Researchers at Epitracker have proposed that C15 may function as an essential dietary fat, pointing to its ability to integrate into cell membranes, act as a partial agonist at PPAR-alpha and PPAR-delta receptors, and potentially reduce cellular processes linked to ferroptosis and senescence. These proposed mechanisms have attracted growing interest, including from women wondering whether C15 is relevant to hormonal balance, fertility, and safe use during pregnancy or while nursing.
The honest answer is that the research base specifically examining C15 in women’s reproductive health is still very limited. Most published work on C15 comes from epidemiological studies of dairy intake or early mechanistic research, and the hypothesis that C15 is ‘essential’ has not been formally adopted by regulatory agencies or mainstream nutrition bodies. This article reviews what is genuinely known, where the evidence stops, and what women should consider before supplementing, especially during pregnancy or breastfeeding.
Key Takeaways
- C15 is a naturally occurring odd-chain fatty acid with proposed mechanisms including cell membrane integration, partial PPAR-alpha/delta activation, and potential reduction of ferroptosis, but these remain early-stage findings.
- One observational study found associations between maternal plasma phospholipid saturated fatty acids in early pregnancy and fetal growth, but this does not establish that C15 supplementation is safe or beneficial during pregnancy [1].
- No clinical trials have examined C15 supplementation in pregnant or breastfeeding women; the data gap here is real, and caution is warranted.
- The idea that C15 is an ‘essential’ fatty acid is a hypothesis from Epitracker researchers and has not been adopted by regulatory agencies or mainstream nutrition science bodies.
- Women who are pregnant, breastfeeding, or managing hormonal conditions should consult a healthcare provider before adding C15 supplements to their routine.
What Is C15 and How Might It Affect the Body?
C15 is a 15-carbon saturated fatty acid that occurs in small amounts in the fat of ruminant animals and in full-fat dairy. Unlike most dietary saturated fats, which have an even number of carbons, C15 is an odd-chain fatty acid, a structural difference that gives it distinct metabolic behavior. It is metabolized via a pathway called propionate metabolism rather than acetyl-CoA synthesis, which may reduce its tendency to contribute to fat accumulation in the way even-chain saturated fats can.
Epitracker researchers have proposed that C15 supports cellular integrity by incorporating into red blood cell and other cell membranes, where it may reduce fragility. They also suggest it activates PPAR-alpha and PPAR-delta receptors (nuclear receptors involved in regulating fatty acid oxidation, inflammation, and energy metabolism) at partial agonist levels. Additionally, early research suggests C15 may inhibit ferroptosis, a form of iron-dependent cell death, and reduce markers of cellular senescence. These are proposed mechanisms, not established clinical benefits, and they have not yet been validated in large, long-term human trials.
C15 and Hormonal Health: Plausible Pathways, Limited Direct Evidence
Women often ask about C15 in the context of hormonal balance, partly because PPAR receptors play roles in metabolic regulation that can intersect with hormonal signaling. PPAR-alpha activation is associated with improved lipid metabolism and reduced systemic inflammation, both of which can influence the hormonal environment indirectly. PPAR-delta has roles in energy homeostasis and may affect insulin sensitivity. To the extent that C15 acts as a partial PPAR agonist, there is a theoretical rationale for investigating its influence on metabolic hormones like insulin.
Research note: In the pooled cohort analysis, the inverse links of pentadecanoic and heptadecanoic acid to diabetes were present in both sexes but stronger in women than in men [13].
However, there are currently no published human clinical trials examining C15 supplementation and sex hormone levels (estrogen, progesterone, testosterone, or luteinizing hormone) in women. Any claims connecting C15 directly to improved hormonal balance, cycle regularity, or menopause symptom relief go beyond what the current published evidence supports. Women with hormonal conditions such as polycystic ovary syndrome (PCOS) or endometriosis should not expect C15 to address those conditions based on available data.
C15 During Pregnancy: Observational Data and What It Means
One published study offers relevant data for pregnant women. A 2023 analysis from a multi-racial and multi-ethnic US birth cohort examined associations between early pregnancy maternal plasma phospholipid saturated fatty acids, including odd-chain fatty acids, and fetal growth outcomes [1]. The study found that levels of saturated fatty acids in maternal plasma phospholipids during early pregnancy were associated with fetal growth measures, suggesting that the maternal fatty acid profile during this critical developmental window may be relevant to fetal outcomes.
The few pregnancy findings do not point toward taking more C15
Higher in small babies
C15:0 was higher in mothers and newborns when the baby was small for gestational age.
Lower motor scores
More C15:0 in breast milk at 42 days went with lower infant motor scores (β −4.27).
Mild insulin resistance
Pregnant and nursing mice fed 1% C15:0 developed mild insulin resistance.
Mild glucose intolerance
C15:0 caused mild glucose intolerance without changing body composition.
Until there is a trial, pregnancy is a reason to skip C15 supplements, not to start them.
The human results are associations; the mouse results may not apply to people. Source: Cinelli et al., Nutrients 2018; Bi et al., European Journal of Nutrition 2026; Wang et al., Food & Function 2024 and 2025.
Chart: c15hub.com: The few pregnancy findings do not point toward taking more C15
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
It is important to interpret this finding carefully. The study was observational, meaning it identified associations rather than proving that any fatty acid caused better or worse fetal growth. It examined fatty acids as measured naturally in maternal plasma, not as supplements, and it included multiple saturated fatty acids alongside C15. This data does not establish that supplementing with C15 during pregnancy improves fetal outcomes, nor does it establish safety at supplemental doses in pregnant women [1].
No clinical trials have tested C15 supplementation specifically in pregnant women. The one trial of C15 on its own used 200 mg a day in non-pregnant adults. Because pregnancy involves significant physiological changes that affect nutrient metabolism, absorption, and the consequences of any intervention, the absence of pregnancy-specific safety data is a meaningful gap. Women who are pregnant should consult their obstetrician or midwife before adding C15 supplements to their routine.
Gestational Diabetes and Fetal Growth: What the Human Cohorts Show
Several studies looked at odd-chain fatty acids and gestational diabetes (GDM). In the NICHD Fetal Growth Studies, 107 women who later developed GDM were matched to 214 controls. From gestational week 10, odd-chain saturated fats were lower in the women who went on to develop GDM. Comparing the highest with the lowest quartile at weeks 10 to 14, the adjusted odds ratio for GDM was 0.32 for pentadecanoic acid (95% CI 0.11 to 0.92).[2] A hospital-based case-control study in Wuhan with 217 cases and 217 controls found lower C15 in women with GDM, and a fatty acid pattern weighted toward odd-chain fatty acids was associated with lower odds of the condition (adjusted OR 0.42 for the top versus bottom quartile).[3]
The Nutrients cohort already cited above also reported that, compared with the lowest tertile, women in the highest tertile of early-pregnancy C15 had a greater fetal weight and size from week 13 onward, with an estimated fetal weight of 3,429.89 g versus 3,269.08 g at week 39.[1]
Not every pregnancy signal points the same way. In several hundred mother-infant pairs, higher C15 in red blood cells (in mothers and newborns) was found in small-for-gestational-age babies compared with appropriate-size babies, an unexpected association that runs against a more-is-better reading (observational) [11].
A 2026 matched case-control study in Shenzhen compared 290 women with GDM and 580 with normal glucose tolerance, matched on maternal age and pre-pregnancy BMI. Total odd-chain fatty acids again showed a protective association, but the strongest single signals came from other fats: the medium-chain fats C12:0 and C14:0 were inversely associated with GDM risk (the highest quartile of C12:0 with 48% lower risk), while the very-long-chain fats C22:0 and C24:0 were positively associated, with the highest quartile of C22:0 carrying a more than two-fold higher risk.[6] The odd-chain group agrees in direction across these cohorts, but this one does not single out C15 as the most informative marker.
How a result is reported can also change its direction. In a cross-sectional study of 273 women in the second trimester, serum non-esterified fatty acids were expressed both as absolute concentrations and as a proportion of total fatty acids. Glucose intolerance was positively associated with odd-chain non-esterified fatty acids as absolute concentrations (r = 0.21) and inversely associated when they were expressed as a proportion (r = -0.31). The authors concluded that relative proportions worked better as biomarkers and called for more research on the inconsistency.[7] This is a different blood fraction from the phospholipids measured in the cohorts above, so it does not overturn them, but it shows that the same fat can look protective or harmful depending on how it is reported.
All of these studies are observational. They measured blood C15 that women accumulated through ordinary diet and metabolism, which can track dairy-rich eating patterns or overall diet quality. They cannot show that raising C15 with a supplement would lower anyone’s GDM risk or change fetal growth.
Mouse Studies in Pregnancy: A Vascular Signal and a Glucose Trade-Off
The animal data point in a less reassuring direction. In a 2024 Food and Function study, pregnant mice fed a diet containing 1% C15 had higher C15 and C17:0 in maternal plasma, fetal tissue and offspring plasma, with no effect on embryonic development. The mothers developed mild insulin resistance during pregnancy, and during lactation showed mild insulin resistance and oxidative stress. Offspring grew faster, and their plasma and liver triglycerides fell. The authors concluded that 1% C15 mildly lowered maternal glucose tolerance, mainly through PPAR-alpha and MAPK signaling.[4]
A 2025 study in the same journal fed pregnant mice a 60% kcal high-fat diet with or without 1% C15 ethyl ester. Supplemented animals again showed mild glucose intolerance at the 90 and 120 minute marks, with body composition, fasting insulin, HOMA-IR and plasma lipids unchanged. Vascularization of the placental labyrinth zone rose, but at P = 0.052, just outside conventional significance. Fetal cholesterol transport (P = 0.002), PI3K-AKT signaling and pro-angiogenic gene expression were increased. In cultured endothelial cells, C15 at 12.5 micromolar promoted tube formation, an effect abolished by a PI3K inhibitor, while heptadecanoic acid (C17:0) had no such effect and inhibited the cells at 12.5 to 25 micromolar.[5]
Both papers used the same 1% dietary dose in the same species, and both found mild worsening of glucose handling alongside a possible benefit: better offspring lipids in one, more placental vessel formation in the other. Two mouse studies are not a clinical finding, and 1% of the diet by weight is a large intake. They do make the glucose signal harder to dismiss as a one-off, and together they describe a trade-off in animals, not a clean win. The C15 versus C17:0 contrast is also a reminder that the two odd-chain fats are often treated as interchangeable dairy markers but did not behave alike in these cells.
Reconciling the Mouse and Human Evidence
The two bodies of evidence ask different questions. The cohorts link naturally higher blood C15 with fewer GDM diagnoses; the mouse studies gave a large supplemental dose to pregnant animals and observed what changed. Neither design tells us what a capsule does in a pregnant woman, and no randomized trial in pregnancy appears to have been published. A study able to answer it would need to enroll pregnant women, choose a dose grounded in dietary intake or in the blood levels seen in the cohorts, separate women with low starting C15 from those with ample levels, and follow glucose tolerance, fetal growth and offspring outcomes.
Some brands state that because C15 is a GRAS ingredient it is safe in pregnancy and while nursing. GRAS is a regulatory pathway for food ingredients, not a pregnancy trial, and given the mild glucose finding in two animal papers and the lack of human pregnancy data, the cautious reading is that the question remains open. Decisions about supplements during pregnancy belong with an obstetric provider who knows your glucose screening results and history.
Breastfeeding and C15: A Recognized Data Gap
Breast milk contains C15, but how closely it follows a mother’s diet is unclear: in one breast-milk cohort, maternal milk intake was negatively correlated with breast-milk pentadecylic acid, not positively [8]. Whether deliberately supplementing with C15 at doses of 100 to 300 mg per day would meaningfully alter breast milk C15 levels or affect infant outcomes has not been studied in published research.
One observational cohort found that higher breast-milk C15 at 42 days was linked to lower infant motor development scores, the opposite of a benefit story. It does not show that C15 caused the difference, but it is a reason not to assume that more C15 in milk helps infants [12].
There are no published clinical trials or safety studies evaluating C15 supplementation in breastfeeding women or in infants receiving breast milk from supplementing mothers. This is a genuine data gap, not a reassuring absence of negative findings. Until studies specifically evaluate safety and potential benefit in this population, caution is warranted. Breastfeeding women should discuss any fatty acid supplementation with their healthcare provider.
General Safety Profile of C15 Supplements
The one small randomized trial of C15 alone, in 30 non-pregnant adults taking 200 mg a day for 12 weeks and supported by the company that supplied the capsules, reported no significant adverse events [9]. Fatty15 is the brand name of a company’s capsule product, which the company describes as pure FA15 powder made by chemical synthesis [10]. Because C15 is a fat, it is best absorbed when taken with food containing other dietary fats.
The FDA has not evaluated C15 supplements for the treatment or prevention of any disease. The classification of C15 as an ‘essential’ fatty acid is a scientific hypothesis put forward by Epitracker researchers and has not been formally recognized by the FDA, the European Food Safety Authority, or mainstream nutrition science bodies as of the time of writing. Women with existing liver or metabolic conditions, or those taking medications that affect lipid metabolism, should discuss C15 with a clinician before use.
Dietary Sources Versus Supplementation: A Practical Consideration for Women
For women who consume dairy, the most established way to obtain C15 is through full-fat dairy foods such as whole milk, butter, cheese, and yogurt made from ruminant milk. Fatty fish and some ruminant meats also contain small amounts. Dietary intake from these sources comes packaged with other nutrients, fatty acids, and food matrix effects that may modulate how C15 is absorbed and used.
Supplementation offers a way to achieve a defined daily dose without the caloric load of high dairy intake, which may appeal to women managing weight or avoiding dairy for other reasons. However, the epidemiological evidence linking higher circulating C15 to health outcomes is largely derived from populations with dietary C15, not from supplementation studies. Whether the supplement form produces equivalent physiological effects is a question that ongoing research is beginning to address but has not yet definitively answered.
🛒 Where to Buy Pentadecanoic Acid (C15)
- Fatty15 (official site) 20% off with code SFKKDBQQ
capsules, 100 mg C15 per capsule; 1 capsule/day starter, 2 capsules/day maintenance: Category creator, from the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15
capsules, 200 mg C15 per serving (2 capsules): Generic C15 supplement; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15
softgels, 100 mg C15 per softgel: Established supplement brand with strong Amazon presence; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15)
powder, 100 to 300 mg per measured serving: Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. C15 products vary widely in how much pentadecanoic acid they actually contain, so check that the Supplement Facts panel lists C15 in milligrams as its own line item rather than bundling it into a fatty acid blend, and that the per-serving dose falls in the 100 to 300 mg range used in published research.
A Note on the Evidence
The evidence base for C15 in women’s health, particularly during pregnancy and breastfeeding, is very limited, and no regulatory body has approved C15 supplements for any health condition. Women who are pregnant, breastfeeding, trying to conceive, or managing hormonal or metabolic conditions should consult a qualified healthcare provider before starting C15 supplementation. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Can C15 help balance hormones in women?
There is no published clinical trial evidence showing that C15 supplementation directly improves sex hormone levels or resolves hormonal imbalances in women. The proposed PPAR-alpha and PPAR-delta agonist activity of C15 is theoretically relevant to metabolic regulation, but this has not been translated into demonstrated effects on estrogen, progesterone, or other reproductive hormones in human studies.
Is it safe to take C15 while pregnant?
No clinical trials have tested C15 supplementation during pregnancy, so safety at supplemental doses in pregnant women is not established. An observational study did examine associations between maternal plasma odd-chain fatty acids and fetal growth outcomes [1], but that data does not confirm supplementation safety. Pregnant women should consult their obstetrician before use.
Can I take C15 while breastfeeding?
There are no published studies evaluating C15 supplementation in breastfeeding women or its effects on breast milk composition or infant outcomes. Until that data exists, breastfeeding women should speak with a healthcare provider before supplementing.
Does C15 appear naturally in breast milk?
Odd-chain fatty acids including C15 are present in small amounts in human breast milk, though how closely this follows maternal diet is not clear [8]. Women who consume full-fat dairy and ruminant foods will naturally have some C15 in their diet and breast milk, but the effect of deliberate high-dose supplementation on breast milk composition has not been published in the available literature.
What dose of C15 has been studied in adults?
The one small randomized trial of C15 alone used 200 mg a day for 12 weeks in 30 non-pregnant adults and reported no significant adverse events [9]. These studies were not conducted in pregnant or breastfeeding populations, so these tolerability findings cannot be automatically extended to those groups.
Does C15 act like a hormone or affect the endocrine system?
C15 is not a hormone, but as a proposed partial PPAR-alpha and PPAR-delta agonist it may interact with nuclear receptor signaling pathways that overlap with metabolic and inflammatory regulation. Whether this produces meaningful effects on the endocrine system in humans has not been demonstrated in clinical trials. This remains an area of early-stage research.
Do higher natural C15 levels in pregnancy protect against gestational diabetes?
Observational studies found lower gestational diabetes odds in women with higher plasma C15, for example an adjusted odds ratio of 0.32 for the highest versus lowest quartile in a US cohort.[2] These are associations and do not show that a supplement would have the same effect.
Did C15 supplements harm pregnant mice?
Two Food and Function papers reported mild glucose intolerance or insulin resistance in pregnant mice fed 1% C15, with no effect on embryonic development in the 2024 study.[4][5] The mice also showed some possibly beneficial changes in offspring lipids and placental vessel formation.
Has C15 supplementation been tested in pregnant women?
No randomized trial in pregnancy was found, and the published human supplementation trials did not describe pregnant participants.
References
- Li LJ et al. Early Pregnancy Maternal Plasma Phospholipid Saturated Fatty Acids and Fetal Growth: Findings from a Multi-Racial/Ethnic Birth Cohort in US. Nutrients (2023). PMID 37571228
- Zhu Y et al. A prospective and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes. The American journal of clinical nutrition (2018). PMID 29868913
- Li P et al. Associations of Plasma Fatty Acid Patterns During Pregnancy With Gestational Diabetes Mellitus. Frontiers in nutrition (2022). PMID 35600822
- Wang J et al. Pentadecanoic acid (C15:0, PA) induces mild maternal glucose intolerance and promotes the growth of the offspring partly through up-regulating liver PPARα and MAPK signaling pathways. Food & function (2024). PMID 39434548
- Wang C et al. Pentadecanoic acid (C15:0) promotes placental angiogenesis by activating the placental PI3K-AKT signaling. Food and function (2025). PMID 41221667
- Luo J et al. Associations of mid-pregnancy plasma fatty acid patterns with gestational diabetes mellitus risk: A 1:2 matched case-control study. Clinical nutrition (2026). PMID 42815206
- Azab SM et al. Non-esterified fatty acids as biomarkers of diet and glucose homeostasis in pregnancy: The impact of fatty acid reporting methods. Prostaglandins, leukotrienes, and essential fatty acids (2022). PMID 34871861
- De Bernardo G et al. Fatty Acid Profiling of Breast Milk at Different Gestational Ages. Nutrients (2025). PMID 40871700
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Fatty15 (Seraphina Therapeutics) Fatty15 FAQs. Fatty15 (Seraphina Therapeutics) (2026). source
- Cinelli G et al. Association between Maternal and Foetal Erythrocyte Fatty Acid Profiles and Birth Weight. Nutrients (2018). PMID 29570689
- Bi Y et al. Odd- and branched-chain fatty acids in breast milk and neurodevelopment in early infancy: a prospective cohort study. European journal of nutrition (2026). PMID 42965676
- Imamura F et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS medicine (2018). PMID 30303968
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.